14 patents currently held
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2037. from the record
Of the 6 now held by other companies, 6 name I Mab Biopharma Hangzhou Co. Ltd. as their current owner. Each row says so.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jun 2037
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2037 · High confidence
Also notable
Ends Jan 2038 · High confidence
Also notable
Ends Sep 2039 · High confidence
Also notable
Ends Aug 2040 · High confidence
Also notable
Ends Sep 2039 · High confidence
Also notable
Ends Apr 2040 · High confidence
Also notable
Ends Mar 2038 · High confidence
ANTI-PD-L1 Antibodies and Uses Thereof
US 10,059,769
The most cited patent in this portfolio, cited by 13 later US patents, top 25% of utility patents granted in 2018 in our data. Protection runs to 2037.
ANTI-CD73 Antibodies and Uses Thereof
US 10,584,169
Cited by 10 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2038.
ANTI-PD-L1 Antibodies and Uses Thereof
US 11,220,546
Granted 2022. Computed term ends 2039.
Anti-Claudin 18.2 and ANTI-4-IBB Bispecific Antibodies and Uses Thereof
US 11,261,259
Granted 2022. Computed term ends 2040.
ANTI-CXCL13 Antibodies
US 11,028,164
Granted 2021. Computed term ends 2039.
Human PD-L1 Antibodies
US 11,208,486
Granted 2021. Computed term ends 2040.
Novel CD47 Monoclonal Antibodies and Uses Thereof
US 12,091,467
A family of 9 related applications built on the 2024 grant. Too new for citation comparison; protection runs to 2038.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Sep 10 to 12, 2027 · next Sep 10
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| ANTI-PD-L1 Antibodies and Uses Thereof (2018) | 3 in force | to Jun 2037 |
| Anti-Claudin 18.2 and ANTI-4-IBB Bispecific Antibodies and Uses Thereof | 2 in force | to Jun 2042 |
| ANTI-CXCL13 Antibodies | 2 in force | to Nov 2041 |
| ANTI-CD73 Antibodies and Uses Thereof | 2 in force | to Mar 2039 |
| ANTI-PD-L1/ANTI-4-1BB Bispecific Antibodies and Uses Thereof | 1 in force | to May 2041 |
| Human PD-L1 Antibodies | 1 in force | to Apr 2040 |
| ANTI-PD-L1 Antibodies and Uses Thereof (2019) | 1 in force | to Sep 2039 |
| Novel CD47 Monoclonal Antibodies and Uses Thereof | 1 in force | to Mar 2038 |
| Anti-Gm-Csf Antibodies and Uses Thereof | 1 in force | to Sep 2037 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,059,769 | ANTI-PD-L1 Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,208,119 | ANTI-PD-L1 Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,723,799 | ANTI-PD-L1 Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,926,662 | Anti-Gm-Csf Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,584,169 | ANTI-CD73 Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,091,467 | Novel CD47 Monoclonal Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,613,577 | ANTI-CD73 Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,220,546 | ANTI-PD-L1 Antibodies and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,028,164 | ANTI-CXCL13 Antibodies In force · High confidence | In force | High confidence | |
| US 11,208,486 | Human PD-L1 Antibodies In force · High confidence | In force | High confidence |
Also on record, not counted in the 14: 6 patents in force now held by others · 2 patents ended · 10 applications pending · 13 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.